Claudia Gagliani, Paul Brinkman, Marco Del Riccio, Alida Benfante, Shahriyar Shahbazi Khamas, Anke-H Maitland-van der Zee, Stefania Principe, Nicola Scichilone
{"title":"呼气冷凝水标记物在严重哮喘管理中的进展:系统综述。","authors":"Claudia Gagliani, Paul Brinkman, Marco Del Riccio, Alida Benfante, Shahriyar Shahbazi Khamas, Anke-H Maitland-van der Zee, Stefania Principe, Nicola Scichilone","doi":"10.1080/17476348.2025.2522743","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Severe asthma is a chronic respiratory disease posing challenges for clinicians and patients, increasing health-care costs and patients' poor quality of life. Advances in precision medicine have introduced novel approaches to managing severe asthma, including breathomics, a promising field using exhaled breath analysis to identify disease biomarkers. Among these techniques, exhaled breath condensate (EBC) analysis has emerged as a potential noninvasive tool for monitoring airway inflammation and disease progression.</p><p><strong>Methods: </strong>A systematic literature review was conducted to identify EBC biomarkers for monitoring severe asthma, searching across PubMed, Cochrane, Google Scholar, MEDLINE, ISRCTN, EMBASE and Web of Science.</p><p><strong>Results: </strong>Twenty-three studies were included in the review. Key markers identified were 8-isoprostane, hydrogen peroxide (H₂O₂), nitric oxide (NO), and eicosanoids. Among these, 8-isoprostane was the most widely studied biomarker in severe asthma, while H₂O₂ seems to be most closely linked to assessing asthma control.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first systematic review focusing on EBC biomarkers in severe asthma. Breath analysis represents a promising noninvasive approach to evaluate airway inflammation, identify early signs of poorly controlled asthma and monitor treatment response. Further research is needed to validate these biomarkers for clinical application.</p><p><strong>Protocol registration: </strong>uk/prospero with identifier CRD42023406669 https://www.crd.york.ac.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-12"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in exhaled breath condensate markers for severe asthma management: a systematic review.\",\"authors\":\"Claudia Gagliani, Paul Brinkman, Marco Del Riccio, Alida Benfante, Shahriyar Shahbazi Khamas, Anke-H Maitland-van der Zee, Stefania Principe, Nicola Scichilone\",\"doi\":\"10.1080/17476348.2025.2522743\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Severe asthma is a chronic respiratory disease posing challenges for clinicians and patients, increasing health-care costs and patients' poor quality of life. Advances in precision medicine have introduced novel approaches to managing severe asthma, including breathomics, a promising field using exhaled breath analysis to identify disease biomarkers. Among these techniques, exhaled breath condensate (EBC) analysis has emerged as a potential noninvasive tool for monitoring airway inflammation and disease progression.</p><p><strong>Methods: </strong>A systematic literature review was conducted to identify EBC biomarkers for monitoring severe asthma, searching across PubMed, Cochrane, Google Scholar, MEDLINE, ISRCTN, EMBASE and Web of Science.</p><p><strong>Results: </strong>Twenty-three studies were included in the review. Key markers identified were 8-isoprostane, hydrogen peroxide (H₂O₂), nitric oxide (NO), and eicosanoids. Among these, 8-isoprostane was the most widely studied biomarker in severe asthma, while H₂O₂ seems to be most closely linked to assessing asthma control.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first systematic review focusing on EBC biomarkers in severe asthma. Breath analysis represents a promising noninvasive approach to evaluate airway inflammation, identify early signs of poorly controlled asthma and monitor treatment response. Further research is needed to validate these biomarkers for clinical application.</p><p><strong>Protocol registration: </strong>uk/prospero with identifier CRD42023406669 https://www.crd.york.ac.</p>\",\"PeriodicalId\":94007,\"journal\":{\"name\":\"Expert review of respiratory medicine\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert review of respiratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17476348.2025.2522743\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17476348.2025.2522743","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:严重哮喘是一种慢性呼吸系统疾病,给临床医生和患者带来了挑战,增加了医疗保健成本,使患者的生活质量下降。精准医学的进步已经引入了治疗严重哮喘的新方法,包括呼吸组学,这是一个很有前途的领域,利用呼气分析来识别疾病生物标志物。在这些技术中,呼气冷凝水(EBC)分析已成为监测气道炎症和疾病进展的潜在无创工具。方法:通过检索PubMed、Cochrane、谷歌Scholar、MEDLINE、ISRCTN、EMBASE和Web of Science,进行系统文献综述,确定EBC生物标志物用于监测重度哮喘。结果:共纳入23项研究。鉴定的关键标记物是8-异前列腺素、过氧化氢(H₂O₂)、一氧化氮(NO)和类二十烷。其中,8-异前列腺素是重度哮喘研究最广泛的生物标志物,而h2o2似乎与评估哮喘控制最密切相关。结论:据我们所知,这是第一个关注EBC生物标志物在严重哮喘中的系统综述。呼吸分析是一种很有前途的无创方法来评估气道炎症,识别控制不良的哮喘的早期迹象和监测治疗反应。需要进一步的研究来验证这些生物标志物的临床应用。协议注册:uk/prospero,标识符CRD42023406669www.crd.york.ac。
Advances in exhaled breath condensate markers for severe asthma management: a systematic review.
Background: Severe asthma is a chronic respiratory disease posing challenges for clinicians and patients, increasing health-care costs and patients' poor quality of life. Advances in precision medicine have introduced novel approaches to managing severe asthma, including breathomics, a promising field using exhaled breath analysis to identify disease biomarkers. Among these techniques, exhaled breath condensate (EBC) analysis has emerged as a potential noninvasive tool for monitoring airway inflammation and disease progression.
Methods: A systematic literature review was conducted to identify EBC biomarkers for monitoring severe asthma, searching across PubMed, Cochrane, Google Scholar, MEDLINE, ISRCTN, EMBASE and Web of Science.
Results: Twenty-three studies were included in the review. Key markers identified were 8-isoprostane, hydrogen peroxide (H₂O₂), nitric oxide (NO), and eicosanoids. Among these, 8-isoprostane was the most widely studied biomarker in severe asthma, while H₂O₂ seems to be most closely linked to assessing asthma control.
Conclusions: To the best of our knowledge, this is the first systematic review focusing on EBC biomarkers in severe asthma. Breath analysis represents a promising noninvasive approach to evaluate airway inflammation, identify early signs of poorly controlled asthma and monitor treatment response. Further research is needed to validate these biomarkers for clinical application.
Protocol registration: uk/prospero with identifier CRD42023406669 https://www.crd.york.ac.